Venetoclax is a BCL2 inhibitor that, despite an incidence of severe infections of 17% and grade 4 neutropenia in 41% of the patients in a stage I trial in R/R CLL,21 does not show a higher incidence of IFI or CMV reactivation.22 This evidence concerns the gene BCL2 and infection.